Navigation Links
Shire Proposes to Expand Specialist Gastrointestinal Portfolio
Date:8/3/2010

in Europe with the recently launched RESOLOR(R) (prucalopride), a new chemical entity. RESOLOR is approved in the 27 countries of the European Union as well as Iceland, Lichtenstein and Norway and is indicated for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. Movetis has the rights to RESOLOR in the EU, Iceland, Lichtenstein, Norway and Switzerland and is entitled to royalties on sales of RESOLOR outside of Europe from Johnson & Johnson.

Mike Cola, President of Shire's Specialty Pharmaceuticals business, comments:

"This proposed acquisition of Movetis provides a highly complementary fit for our GI business unit and supports our strategy of expanding our specialty product portfolio into international markets. This is aligned with our strategy of developing and commercializing medicines to address symptomatic diseases treated by specialist physicians, in this case gastroenterologists. The acquisition of Movetis will provide immediate revenue from a newly-launched product that has strong patent protection, as well as a promising GI pipeline."

Terms of the Offer

Shire will offer EUR19 per share in cash for all of the issued shares of Movetis, valuing the company's fully diluted equity at EUR428 million (as at March 31, 2010, their last reporting date, Movetis held EUR100 million in cash; based on this the enterprise value (less cash) of Movetis would be

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
2. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
3. Shire plc Appoints Two New Board Directors
4. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
5. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
6. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
7. Shires Replenished Portfolio Drives Excellent Quarterly Performance
8. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
9. Shire Supports Rare Disease Day 2010
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 Erlab , the ... since 1968 and Burdinola, supplier of laboratory furniture solutions, ... filtered fume hood. , By integrating ... Burdinola will now offer an innovative solution utilizing the ... of chemicals, best-in-class detection technology, and communication for security ...
(Date:9/23/2014)... 23, 2014 For the fifth time since ... list of the fastest-growing companies. , “We’re so proud ... again by Inc. Magazine,” ExakTime CEO Tony Pappas said. , ... posting a three-year growth rate of 61 percent from 2010 ... by more than 40 percent. , Pappas cited strong performance ...
(Date:9/23/2014)... 23, 2014  Age Defying Dermatology ® , owned ... become one of the first clinics in the Bay ... laser for tattoo removal. The treatment safely and effectively ... years, tattoo removal has been a lengthy, painful, and ... is an opportunity to erase tattoo pigment more efficiently ...
(Date:9/23/2014)... Cambridge Semantics, the leading provider of Smart Data ... the recent ‘Hype Cycle for Life Sciences 2014 ’ ... key insights pertaining to the benefits in the knowledge ... Shanler and Stephen Davies, “The use of these systems ... scientific stakeholders, and support collaboration and innovation strategies as ...
Breaking Biology Technology:Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2ExakTime Makes Inc. 5000 List for the Fifth Time 2Age Defy Now Offers World's Most Advanced Technology for Tattoo Removal 2Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2
... Aug. 20 Vical Incorporated,(Nasdaq: VICL ) ... with,the appointment of Andrew R. de Guttadauro as ... Mr. de Guttadauro was Senior Director of,Strategy at ... overseeing the commercial development of that company,s Zevalin,the ...
... with Sales Team Forming and Increased Space, Poised for ... Medical Technologies,Inc., which is developing innovative devices for the ... a VP of Sales, Joseph W.,Rafferty, and has started ... its first product, Pathway PV(TM) Atherectomy System. Recently ...
... and CLAREMONT, Calif., Aug. 14 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... the second quarter of 2007 increased more than,35% over ... 139 times,revenues of just $13,351 for the same period ... half of 2007 were $3,256,000 compared to only,$24,374 in ...
Cached Biology Technology:Vical Names Andrew de Guttadauro Vice President, Corporate Development 2Vical Names Andrew de Guttadauro Vice President, Corporate Development 3Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6
(Date:9/22/2014)... ATLANTA September 23, 2014 A new American ... Supplemental Nutrition Assistance Program (SNAP), previously known as ... scores compared with income eligible non-participants. The authors ... programs aimed at enhancing the dietary quality of ... assist low-income individuals and households with the resources ...
(Date:9/22/2014)... Yale University researchers are studying a potential new ... respiratory disease in which scars develop in the lungs ... microRNA mimic, miR-29, which is delivered to lung tissue ... fibrosis, it reversed fibrosis after several days. , ... EMBO Molecular Medicine . , "The mimic, when ...
(Date:9/22/2014)... sequencing technologies continue to evolve rapidly, becoming part of ... appropriate policies and regulatory frameworks to address potential challenges, ... issue of the Journal of Law, Medicine & ... with the Center for Medical Ethics and Health Policy ... tools to jumpstart this process. , Experts with ...
Breaking Biology News(10 mins):Federal food program puts food on the table, but dietary quality could be improved 2Reversing the effects of pulmonary fibrosis 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3
... an Israeli start-up company, launched its first "solar farm" near ... systems developed by Prof. David Faiman of Ben-Gurion University ... Faiman, who is chairman of the Department of ... for Desert Research, believes the new system will harvest more ...
... for the 61st Annual Meeting of the Rocky Mountain ... 11-13 May 2009 in Orem, Utah. Utah Valley ... library building on the UVU campus. Brigham Young University ... and industry scientists, and graduate and undergraduate students, will ...
... Ill. Researchers at the University of Illinois have ... one or more molecules into the cytoplasm or the ... amounts of cargo, the nanoneedle can also be used ... "Nanoneedle-based delivery is a powerful new tool for studying ...
Cached Biology News:Ben-Gurion University research and technology used in new solar energy farm 2Geoscientists meet to discuss Rocky Mountain geology 2Nanoneedle is small in size, but huge in applications 2
...
... The Bio-Plex maintenance, calibration, ... is a custom 96-well plate ... validation, and calibration procedures using ... This MCV plate is for ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
... real-time PCR detection system holds 48 x 0.2 ... of 48 LEDs independently excites fluorescence (470-500 nm) ... photodiodes detects emitted light (523-543 nm and 540-700 ... Mini cycler, whose Peltier heat pumps provide superb ...
Biology Products: